Chang-Yuil Kang Selected Research

alpha-galactosylceramide

2/2009	Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
6/2008	alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity.
2/2008	4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation.
1/2008	A distinct subset of natural killer T cells produces IL-17, contributing to airway infiltration of neutrophils but not to airway hyperreactivity.
9/2007	An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
8/2007	Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
8/2007	A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
7/2007	A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
11/2006	CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
9/2005	alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chang-Yuil Kang Research Topics

Disease

31	Neoplasms (Cancer) 11/2021 - 03/2002
7	Infections 01/2019 - 09/2005
5	Virus Diseases (Viral Diseases) 08/2014 - 09/2005
3	Inflammation (Inflammations) 01/2018 - 01/2008
3	Asthma (Bronchial Asthma) 01/2018 - 10/2002
3	Eosinophilia 01/2017 - 05/2010
2	Hypoxia (Hypoxemia) 01/2021 - 05/2005
2	Respiratory Hypersensitivity 01/2017 - 02/2008
2	Lymphoma (Lymphomas) 09/2007 - 07/2004
2	Human Influenza (Influenza) 07/2007 - 09/2005
1	COVID-19 04/2022
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Splenomegaly 01/2020
1	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2017
1	Food Hypersensitivity (Food Allergy) 01/2016
1	Atopic Dermatitis (Atopic Eczema) 01/2016
1	Neoplasm Metastasis (Metastasis) 06/2015
1	Viremia 08/2014
1	Reinfection 08/2013
1	Carcinogenesis 10/2012
1	Rheumatoid Arthritis 10/2012
1	Osteoarthritis 10/2012
1	Hepatitis 07/2012
1	T-Cell Lymphoma (Lymphoma, T Cell) 03/2012
1	Autoimmune Diseases (Autoimmune Disease) 06/2010
1	Pneumonia (Pneumonitis) 02/2008
1	Breast Neoplasms (Breast Cancer) 08/2007
1	Carcinoma (Carcinomatosis) 08/2007
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2004
1	Hepatocellular Carcinoma (Hepatoma) 07/2004
1	Tuberculosis (Tuberculoses) 09/2003

Drug/Important Bio-Agent (IBA)

11	VaccinesIBA 04/2022 - 08/2004
11	alpha-galactosylceramideIBA 02/2009 - 12/2004
10	AntigensIBA 04/2022 - 12/2004
8	LigandsIBA 01/2018 - 12/2004
7	CytokinesIBA 01/2021 - 09/2003
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2004
4	AllergensIBA 01/2018 - 10/2002
4	Galactosylceramides (Galactocerebrosides)IBA 01/2018 - 01/2011
4	Therapeutic UsesIBA 01/2018 - 10/2002
3	Interleukin-17 (Interleukin 17)IBA 01/2021 - 01/2008
3	GlucocorticoidsIBA 01/2020 - 08/2007
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 09/2007
3	AntibodiesIBA 08/2014 - 01/2003
3	Glycoproteins (Glycoprotein)IBA 08/2013 - 08/2004
3	DNA (Deoxyribonucleic Acid)IBA 08/2007 - 01/2003
2	EpitopesIBA 07/2020 - 08/2014
2	Cancer VaccinesIBA 07/2020 - 06/2008
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2020 - 09/2015
2	Interleukin-2 (IL2)IBA 01/2018 - 06/2015
2	Vaccine AdjuvantsIBA 08/2007 - 09/2005
2	member 1 small inducible cytokine subfamily EIBA 05/2005 - 03/2002
1	Topoisomerase I InhibitorsIBA 11/2021
1	Macrophage Colony-Stimulating FactorIBA 11/2021
1	Topotecan (Hycamtin)FDA LinkGeneric 11/2021
1	P-SelectinIBA 01/2021
1	AnticoagulantsIBA 01/2021
1	PlatinumIBA 01/2020
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2020
1	InterleukinsIBA 01/2020
1	InterferonsIBA 01/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2019
1	Fibrinogen (Factor I)FDA Link 01/2018
1	interleukin-21 (interleukin 21)IBA 01/2018
1	Interleukin-12 (IL 12)IBA 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2018
1	Toll-Like Receptor 4IBA 01/2018
1	Interleukin-13IBA 01/2018
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	Pharmaceutical PreparationsIBA 01/2016
1	Interleukin-9 (Interleukin 9)IBA 09/2015
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 09/2015
1	Carcinoembryonic AntigenIBA 06/2015
1	OsteopontinIBA 11/2014
1	Amyloid (Amyloid Fibrils)IBA 06/2014
1	urinary gonadotropin fragmentIBA 08/2013
1	Respiratory Syncytial Virus VaccinesIBA 08/2013
1	Peptides (Polypeptides)IBA 06/2013
1	WD repeat containing planar cell polarity effectorIBA 10/2012
1	CateninsIBA 10/2012
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 07/2012
1	Monoclonal AntibodiesIBA 06/2010
1	Immunoglobulin E (IgE)IBA 05/2010
1	Gemcitabine FDA Link 08/2007
1	AutoantigensIBA 08/2007
1	AerosolsIBA 09/2005
1	Hemagglutinins (Hemagglutinin)IBA 09/2005
1	CD1d AntigensIBA 09/2005
1	DNA VaccinesIBA 09/2005
1	Heparitin Sulfate (Heparan Sulfate)IBA 05/2005
1	OvalbuminIBA 12/2004
1	Detergents (Detergent)IBA 11/2004
1	LipidsIBA 11/2004
1	CholesterolIBA 11/2004
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2004

Therapy/Procedure

10	Immunotherapy 11/2021 - 08/2004
5	Therapeutics 01/2021 - 01/2003
3	Intranasal Administration 08/2013 - 09/2005
1	Combination Drug Therapy (Combination Chemotherapy) 01/2020
1	Drug Therapy (Chemotherapy) 09/2007